The first steps in CD screening should include serological testing of TTG2 IgA, together with total serum IgA, followed by subsequent endomysial antibody (EMA) testing in questionable cases (i.e., low titers, possibly false-positive result of TTG2 IgA, which can occur in other autoimmune diseases, etc.). This evidence concerns the gene CD79A and Cowden disease.